Collegium Pharmaceutical (COLL) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

DEF 14A

Definitive proxy

6 Apr 22

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Climate Risk Environment Environmental Life Cycle Materials Nature Offset Package Packaging Pandemic Planet Raw Materials Recycling Toxic Waste Water Access African American Asian Benefits Black Charitable Charity Collective Bargaining Community Culture Customer Cybersecurity Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Employee Engagement Employee Training Engagement Ethnic Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Opioid Pay Equity Pay for Performance Philanthropy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skills Social Societal Society Stakeholder Supplier Supply Chain Supply Chain Management Talent Training Volunteer Women Workers Workforce Action Plan Assessment Assurance Attorney General Attorneys General Audit Board Oversight Bonus Chronic Classified Clawback Commitment Conflict of Interest Corporate Governance Corporate Purpose Corporate Social Responsibility Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigant Litigation Long-term Majority Materiality Mission Oversee Oversight Plaintiff Pledging Procurement Purpose R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Shareholder Proposals Stewardship Strategy Supermajority Sustainability Sustainable Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

A total of 33,923,148 shares of common stock of Collegium Pharmaceutical, Inc. (the “Company”) were entitled to vote as of March 31, 2022, the record date for the Annual Meeting, of which 31,262,511 were present in person or by proxy at the Annual Meeting. The following is a summary of the final voting results for each matter presented to shareholders.

PROPOSAL 1:

Election of six Directors to hold office until the 2023 Annual Meeting of Shareholders.

Nominee	For	Against	Abstentions	Broker Non-Votes
Rita Balice-Gordon	28,097,111	877,300	42,457	2,245,643
Garen Bohlin	28,898,563	75,467	42,838	2,245,643
John Fallon	27,308,836	1,407,057	300,975	2,245,643
John Freund	28,580,586	393,431	42,851	2,245,643
Neil F. McFarlane	28,911,581	61,054	44,233	2,245,643
Gwen Melincoff	27,860,871	1,109,531	46,466	2,245,643

Each of Rita Balice-Gordon, Garen Bohlin, John Fallon, John Freund, Neil F. McFarlane and Gwen Melincoff was re-elected by the Company’s shareholders as Directors to hold office until the 2023 Annual Meeting of Shareholders.

PROPOSAL 2:

Approval of, on an advisory basis, the compensation of the Company’s named executive officers.

For		Against		Abstentions		Broker Non-Votes
28,337,587		643,459		35,822		2,245,643

On an advisory basis, the Company’s shareholders approved the compensation of the Company’s named executive officers.

PROPOSAL 3:

Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

For		Against		Abstentions		Broker Non-Votes
31,224,033		21,504		16,974		0

Proposal 3 was approved by the Company’s shareholders.